Entering the era of complete genomics and proteomics

GPS Cancer™ is a unique molecular test offered by NantHealth that integrates quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing, of both normal and cancer tissue.

GPS Cancer™, run in CLIA-certified CAP-accredited laboratories, provides oncologists with the most comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies before treatment begins. 

For the first time, clinicians will now be able to measure the presence of protein biomarkers in the patient's tumor cells at an extremely low quantitative level at attomoles per microgram of tumor tissue. Protein biomarkers known to induce drug resistance or indicate drug sensitivity for chemotherapy, monoclonal antibody therapy, hormonal therapy, targeted therapy and immunotherapy can now be identified from patient's tumor tissue (Liquid Tissue™) by the GPS Cancer™ test. These findings will enable personalized cancer care for patients with actionable insights for: 

  • Chemotherapy
  • Monoclonal antibody therapy
  • Hormonal therapy
  • Targeted therapy
  • Immunotherapy

Addressing the question:

Doctor, what information do you have from my tumor tissue that will help inform you that the treatment you are about to prescribe has a probability of being effective?

GPS Cancer™ report:

  • Includes whole genome sequencing of over 20,000 genes and 3 billion base pairs
  • Incorporates whole transcriptome sequencing of over 200,000 RNA transcripts
  • Leverages the power of quantitative proteomics with mass spectrometry
  • Compares a patient’s tumor genome to their normal genome
  • GPS Cancer™ report is available within less than 21 days from receipt of tissue

The GPS Cancer™ test results are available to the ordering physician in less than 21 days from receipt of tissue in a concise format or through a detailed cloud-based genome browser. The GPS Cancer report lists potential treatment options (if applicable), including FDA-approved targeted therapies and active clinical trials with potential for clinical benefit, and/or available therapies to which the cancer may be resistant. The GPS Cancer report does not recommend treatments, and it is the responsibility of the treating physician to develop a personalized treatment plan after discussing available treatment options and the potential risks associated with each treatment option with the patient.

To learn more about GPS Cancer, contact us at 1-844-MY-OMICS / 1-844-696-6427 or GPSCancer@NantHealth.com


Cancer MoonShot 2020

Cancer MoonShot 2020 is the world's most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of the disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020.

GPS Cancer is an enabler for facilitating the goals of Cancer MoonShot 2020 by helping inform oncologists in developing personalized treatment strategies for cancer patients. This will include QUILT (Quantitative Integrative Lifelong Trials), which focuses on the potential of combination immunotherapy as the next-generation standard of care for cancer patients, and forms the clinical basis for the Cancer MoonShot 2020 program.

For more information, visit www.CancerMoonShot2020.org.